262 related articles for article (PubMed ID: 10815932)
1. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells.
Camirand A; Zakikhani M; Young F; Pollak M
Breast Cancer Res; 2005; 7(4):R570-9. PubMed ID: 15987464
[TBL] [Abstract][Full Text] [Related]
3. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas.
Baker CH; Kedar D; McCarty MF; Tsan R; Weber KL; Bucana CD; Fidler IJ
Am J Pathol; 2002 Sep; 161(3):929-38. PubMed ID: 12213721
[TBL] [Abstract][Full Text] [Related]
4. Intravenous administration of manuka honey inhibits tumor growth and improves host survival when used in combination with chemotherapy in a melanoma mouse model.
Fernandez-Cabezudo MJ; El-Kharrag R; Torab F; Bashir G; George JA; El-Taji H; al-Ramadi BK
PLoS One; 2013; 8(2):e55993. PubMed ID: 23409104
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies.
Hurwitz E; Klapper LN; Wilchek M; Yarden Y; Sela M
Cancer Immunol Immunother; 2000 Jul; 49(4-5):226-34. PubMed ID: 10941905
[TBL] [Abstract][Full Text] [Related]
6. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.
Morton CL; Maris JM; Keir ST; Gorlick R; Kolb EA; Billups CA; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2012 Apr; 58(4):566-71. PubMed ID: 21538824
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with nedaplatin and cyclophosphamide in human ovarian cancer model.
Uchida N; Yoshida H; Yamada H; Wada T; Daikatsu K; Ikeuchi I; Maekawa R; Sugita K; Yoshioka T
Jpn J Cancer Res; 1999 Aug; 90(8):887-94. PubMed ID: 10543262
[TBL] [Abstract][Full Text] [Related]
8. RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.
Narendrula R; Mispel-Beyer K; Guo B; Parissenti AM; Pritzker LB; Pritzker K; Masilamani T; Wang X; Lannér C
BMC Cancer; 2016 Feb; 16():146. PubMed ID: 26911141
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model.
Lee YS; Han JM; Kang T; Park YI; Kim HM; Kim S
Mol Cells; 2006 Apr; 21(2):213-7. PubMed ID: 16682815
[TBL] [Abstract][Full Text] [Related]
10. Multi-nanolayer drug delivery using radiofrequency plasma technology.
Al Dybiat I; Baitukha A; Pimpie C; Kaci R; Pocard M; Arefi Khonsari F; Mirshahi M
BMC Cancer; 2020 Jun; 20(1):565. PubMed ID: 32552705
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic Effects on HL-60 Cells of Myosin Light Chain Kinase Inhibitor ML-7 Alone and in Combination with Flavonoids.
Lee JW; Kim YJ; Choi YJ; Woo HD; Kim GE; Ha TK; Lee YH; Chung HW
Toxicol Res; 2009 Dec; 25(4):181-188. PubMed ID: 32038836
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.
Moyer JD; Barbacci EG; Iwata KK; Arnold L; Boman B; Cunningham A; DiOrio C; Doty J; Morin MJ; Moyer MP; Neveu M; Pollack VA; Pustilnik LR; Reynolds MM; Sloan D; Theleman A; Miller P
Cancer Res; 1997 Nov; 57(21):4838-48. PubMed ID: 9354447
[TBL] [Abstract][Full Text] [Related]
14. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG; Jänne PA; Lee JC; Tracy S; Greulich H; Gabriel S; Herman P; Kaye FJ; Lindeman N; Boggon TJ; Naoki K; Sasaki H; Fujii Y; Eck MJ; Sellers WR; Johnson BE; Meyerson M
Science; 2004 Jun; 304(5676):1497-500. PubMed ID: 15118125
[TBL] [Abstract][Full Text] [Related]
15. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
Wakeling AE; Guy SP; Woodburn JR; Ashton SE; Curry BJ; Barker AJ; Gibson KH
Cancer Res; 2002 Oct; 62(20):5749-54. PubMed ID: 12384534
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Giaccone G; Herbst RS; Manegold C; Scagliotti G; Rosell R; Miller V; Natale RB; Schiller JH; Von Pawel J; Pluzanska A; Gatzemeier U; Grous J; Ochs JS; Averbuch SD; Wolf MK; Rennie P; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):777-84. PubMed ID: 14990632
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
19. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer.
von Minckwitz G; Jonat W; Fasching P; du Bois A; Kleeberg U; Lück HJ; Kettner E; Hilfrich J; Eiermann W; Torode J; Schneeweiss A
Breast Cancer Res Treat; 2005 Jan; 89(2):165-72. PubMed ID: 15692759
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; Jänne PA
Cancer Res; 2004 Oct; 64(20):7241-4. PubMed ID: 15492241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
